Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | ECE1 | P42892 | 9/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31184624 | 1.00 | ACE (0.55) | ACEECE1 | |
| SCHEMBL29511163 | 1.00 | ACE (0.55) | ACEECE1 | |
| SCHEMBL29511038 | 0.95 | ACE (0.55) | ACEECE1 | |
| SCHEMBL29511013 | 0.95 | ACE (0.55) | ACEECE1 | |
| SCHEMBL30671629 | 0.95 | ACE (0.56) | ACEECE1 | |
| SCHEMBL29633548 | 0.94 | UTS2R (0.56) | ACE | |
| SCHEMBL30029375 | 0.94 | ERAP2 (0.54) | ACEECE1 | |
| SCHEMBL30775073 | 0.94 | UTS2R (0.54) | ACEECE1 | |
| SCHEMBL30200105 | 0.94 | ACE (0.52) | ACE | |
| SCHEMBL30085020 | 0.94 | ACE (0.52) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151135-A1 | METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4605407-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | Endevica Bio, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025151135-A1 | METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS | ENDEVICA BIO, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2025-06-19 | — | — | US | disclosed |
| WO-2025123059-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR TREATING SUBSTANCE USE DISORDERS | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025123056-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025123055-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024086381-A2 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4216979-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023028538-A1 | MC4R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | ACE 3387/4885ECE1 4276/4885 |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | PCTP, SLC27A1, CETP | ACE 3942/4885ECE1 2948/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | ACE 3407/4885ECE1 2622/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | ACE 1785/4885ECE1 824/4885 |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | ACE 3990/4885ECE1 4217/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | ACE 3249/4885ECE1 1750/4885 |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | ARGLU1, FFAR3, ASNS | ACE 3990/4885ECE1 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.